1 Classification
Heart failure is classified in several ways to describe how the syndrome presents and to guide treatment. Common systems use the ejection fraction, the side of the heart that is predominantly affected, the tempo of onset, and the overall severity of symptoms and functional limitation.
1.1 By ejection fraction
Ejection fraction is the percentage of blood ejected by the ventricle with each contraction. It is a central measure in heart failure because it helps distinguish different patterns of cardiac dysfunction.
1.1.1 Heart failure with reduced ejection fraction
Heart failure with reduced ejection fraction is usually associated with impaired systolic pumping, often from weakened contraction of the left ventricle. It is commonly linked to prior myocardial injury, cardiomyopathy, or long-standing pressure overload.
1.1.2 Heart failure with preserved ejection fraction
Heart failure with preserved ejection fraction occurs when the ejection fraction remains normal or near normal, but the heart fills abnormally or requires higher filling pressures to do so. This form is often related to ventricular stiffening, aging, hypertension, and metabolic disease.
1.1.3 Heart failure with mildly reduced ejection fraction
Heart failure with mildly reduced ejection fraction occupies an intermediate range between reduced and preserved ejection fraction. It may show features of both impaired contraction and abnormal relaxation, and it is often managed with therapies used in reduced ejection fraction.
1.2 By side of the heart
The syndrome may involve the left ventricle, the right ventricle, or both. The dominant side involved influences the pattern of symptoms and physical findings.
1.2.1 Left-sided heart failure
Left-sided heart failure primarily affects pulmonary circulation because blood returning from the lungs is not pumped forward efficiently. Dyspnea, pulmonary congestion, and reduced exercise capacity are typical features.
1.2.2 Right-sided heart failure
Right-sided heart failure leads to systemic venous congestion. It commonly causes peripheral edema, abdominal swelling, liver enlargement, and jugular venous distention.
1.2.3 Biventricular heart failure
Biventricular heart failure involves both ventricles and produces a mixed picture of pulmonary and systemic congestion. It is frequent in advanced disease and may develop after prolonged dysfunction of one side.
1.3 By duration and onset
The course of heart failure may be sudden or gradual. This distinction is important because acute presentations often require urgent intervention, while chronic disease is managed over time.
1.3.1 Acute heart failure
Acute heart failure develops rapidly and may arise in a person with previously stable cardiac function or without prior diagnosis. It often presents with abrupt shortness of breath, pulmonary edema, or shock-like features.
1.3.2 Chronic heart failure
Chronic heart failure is a long-term syndrome with persistent or recurrent symptoms. Patients may remain stable for periods, though symptoms often worsen with progression or intercurrent illness.
1.3.3 Acute decompensated heart failure
Acute decompensated heart failure refers to sudden worsening of established chronic heart failure. It is commonly marked by fluid overload, increased dyspnea, and need for hospitalization.
1.4 By severity
Severity classifications describe the functional impact of symptoms and the stage of structural disease. They are used for prognosis, monitoring, and treatment planning.
1.4.1 New York Heart Association functional classification
The New York Heart Association functional classification grades symptoms according to activity limitation. It ranges from no limitation to symptoms at rest, providing a practical measure of functional capacity.
1.4.2 Stages of heart failure
Staging systems emphasize disease progression from risk factors through established structural disease to advanced symptoms. Unlike symptom grades, stages reflect the underlying severity and likelihood of progression.
2 Causes and risk factors
Heart failure can result from many cardiac and systemic disorders. The most common causes impair the myocardium directly, increase the workload of the heart, or disrupt rhythm and filling.
2.1 Ischemic heart disease
Ischemic heart disease is one of the leading causes of heart failure. Reduced blood supply damages heart muscle and may leave scar tissue that weakens pump function.
2.1.1 Myocardial infarction
Myocardial infarction can cause irreversible loss of contractile tissue. The extent and location of damage influence later ventricular function and the risk of chronic heart failure.
2.1.2 Coronary artery disease
Coronary artery disease produces chronic narrowing of the coronary arteries and recurrent ischemia. Over time, this may lead to ventricular dysfunction, remodeling, and symptoms of heart failure.
2.2 Hypertension
Hypertension increases afterload, forcing the heart to pump against higher resistance. Long-standing pressure overload contributes to hypertrophy, stiffening, and eventual failure.
2.3 Valvular heart disease
Valvular disease alters forward flow or causes backward leakage, both of which strain the heart. Common examples include stenosis and regurgitation of the aortic or mitral valves.
2.4 Cardiomyopathies
Cardiomyopathies are diseases of the heart muscle that may be inherited or acquired. They frequently produce structural changes that impair contraction, relaxation, or both.
2.4.1 Dilated cardiomyopathy
Dilated cardiomyopathy features enlargement of the ventricular chambers and weakened systolic function. It can arise from genetic causes, toxins, infection, or idiopathic mechanisms.
2.4.2 Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is marked by abnormal thickening of the myocardium, often with impaired filling and sometimes obstruction to outflow. It may lead to dyspnea, chest discomfort, and arrhythmia.
2.4.3 Restrictive cardiomyopathy
Restrictive cardiomyopathy causes a stiff ventricle that fills poorly despite relatively preserved contraction early in the disease. It often produces prominent congestion and elevated filling pressures.
2.5 Arrhythmias
Persistent rhythm disturbances can reduce cardiac output and promote structural deterioration. Both fast and irregular rhythms may trigger or worsen heart failure.
2.5.1 Atrial fibrillation
Atrial fibrillation can impair ventricular filling and reduce coordinated atrial contribution to cardiac output. In susceptible individuals, it may precipitate decompensation.
2.5.2 Tachycardia-induced cardiomyopathy
Tachycardia-induced cardiomyopathy results from sustained rapid heart rate. If the arrhythmia is controlled, ventricular function may improve substantially.
2.6 Congenital heart disease
Congenital structural abnormalities may overload the heart from birth or childhood. Some defects are corrected early, while others contribute to heart failure later in life.
2.7 Systemic and metabolic causes
Systemic illnesses can damage the myocardium or alter cardiac loading conditions. Metabolic imbalance may also worsen symptoms in people with underlying heart disease.
2.7.1 Diabetes mellitus
Diabetes mellitus is associated with vascular disease, myocardial dysfunction, and increased risk of ischemic injury. It also commonly coexists with other factors that promote heart failure.
2.7.2 Thyroid disorders
Thyroid dysfunction can affect heart rate, contractility, and vascular resistance. Both excess and deficiency may contribute to cardiac symptoms.
2.7.3 Alcohol and drug toxicity
Excess alcohol and certain drugs may injure cardiac muscle directly. Toxic exposure can produce dilated cardiomyopathy or acute worsening of function.
3 Pathophysiology
Heart failure develops when the heart cannot maintain adequate output without abnormal filling pressures. The syndrome involves mechanical dysfunction, compensatory neurohormonal responses, and progressive changes in structure and fluid balance.
3.1 Cardiac pump dysfunction
The primary problem is reduced efficiency of the pumping chamber, impaired filling, or both. As output falls, tissues receive less oxygen and nutrients, especially during exertion.
3.2 Neurohormonal activation
A fall in effective circulation activates hormonal and autonomic systems meant to preserve blood pressure and perfusion. Although initially compensatory, these responses can intensify congestion and remodel the heart.
3.2.1 Renin-angiotensin-aldosterone system
Activation of the renin-angiotensin-aldosterone system promotes vasoconstriction, sodium retention, and fluid accumulation. Over time, it contributes to fibrosis and worsening ventricular function.
3.2.2 Sympathetic nervous system
The sympathetic nervous system increases heart rate and contractility in an attempt to maintain output. Chronic stimulation, however, may increase oxygen demand and promote adverse remodeling.
3.3 Ventricular remodeling
Ventricular remodeling refers to changes in size, shape, and wall structure after injury or chronic stress. This process may initially support circulation but later becomes maladaptive.
3.4 Fluid and sodium retention
The kidneys retain sodium and water in response to reduced perfusion and hormonal signals. This expands blood volume and aggravates edema and congestion.
3.5 Increased filling pressures
As ventricular compliance declines or volume overload develops, filling pressures rise. Elevated pressures are transmitted backward into the lungs or systemic veins depending on the side affected.
3.6 Organ hypoperfusion and congestion
Reduced forward flow and venous congestion can both impair organ function. Kidneys, liver, lungs, and skeletal muscles are especially vulnerable.
4 Signs and symptoms
The clinical picture of heart failure is usually dominated by breathlessness, fatigue, and fluid retention. Findings vary with severity, speed of onset, and the side of the heart involved.
4.1 Dyspnea
Shortness of breath is a hallmark symptom and often reflects pulmonary congestion or reduced cardiac reserve. It may appear during activity, when lying flat, or suddenly at night.
4.1.1 Exertional shortness of breath
Exertional dyspnea occurs when physical activity exceeds the heart’s ability to increase output. It is often one of the earliest complaints.
4.1.2 Orthopnea
Orthopnea is breathlessness that worsens when lying flat and improves when sitting up. It is typically associated with fluid shifting into the lungs in the recumbent position.
4.1.3 Paroxysmal nocturnal dyspnea
Paroxysmal nocturnal dyspnea is sudden nighttime awakening with severe shortness of breath. It is classically linked to pulmonary congestion and elevated filling pressures.
4.2 Fatigue and exercise intolerance
Fatigue results from poor tissue perfusion and impaired oxygen delivery during activity. Exercise capacity often declines before overt edema becomes obvious.
4.3 Edema and fluid overload
Fluid accumulation is common, especially in right-sided or advanced disease. It may involve the legs, abdomen, and body weight.
4.3.1 Peripheral edema
Peripheral edema usually appears in the ankles or lower legs. It is often worse later in the day and may leave indentations on pressure.
4.3.2 Ascites
Ascites is accumulation of fluid in the abdominal cavity. It is more typical in severe venous congestion.
4.3.3 Weight gain
Rapid weight gain may indicate salt and water retention. It is a useful marker for monitoring fluid status.
4.4 Pulmonary congestion
Fluid in the lungs produces cough, wheeze, and a sensation of air hunger. Severe congestion may progress to pulmonary edema.
4.5 Reduced perfusion
When output is low, organs and extremities may receive insufficient blood flow. Symptoms can include cold skin, dizziness, and cognitive changes.
4.5.1 Cool extremities
Cool hands and feet suggest reduced peripheral perfusion. They are often seen in more advanced low-output states.
4.5.2 Dizziness and confusion
Lightheadedness or confusion may occur when cerebral perfusion is reduced. These symptoms can signal significant decompensation.
4.6 Physical examination findings
Examination often reveals both congestion and reduced circulatory efficiency. Several classic signs help support the diagnosis.
4.6.1 Elevated jugular venous pressure
Raised jugular venous pressure reflects increased right-sided filling pressure. It is a key indicator of venous congestion.
4.6.2 Crackles
Fine lung crackles may be heard over the bases when fluid is present in the alveoli or interstitial spaces. They are common in left-sided congestion.
4.6.3 S3 gallop
An S3 gallop can indicate rapid ventricular filling in a dilated or overloaded ventricle. It is often associated with systolic dysfunction.
4.6.4 Hepatomegaly
An enlarged liver may result from chronic venous congestion. It can be accompanied by tenderness in some cases.
5 Diagnosis
Diagnosis is based on symptoms, examination, and objective testing. Because heart failure has many causes and mimics, evaluation aims to confirm the syndrome and identify its underlying origin.
5.1 Clinical evaluation
The first step is careful assessment of symptoms, risk factors, and signs of congestion or low perfusion. Clinical findings often determine the urgency of further testing.
5.1.1 Medical history
History taking focuses on breathlessness, edema, prior cardiac disease, medications, and precipitating events. Information about hypertension, ischemic disease, arrhythmia, and toxic exposures is especially relevant.
5.1.2 Physical examination
Examination looks for jugular venous distention, edema, displaced apical impulse, pulmonary crackles, and murmurs. Blood pressure, heart rate, weight, and oxygenation are also important.
5.2 Laboratory tests
Laboratory studies help support the diagnosis, assess severity, and identify contributing conditions. They are also useful for monitoring therapy.
5.2.1 Natriuretic peptides
Natriuretic peptides rise with ventricular wall stress and are widely used to support or exclude heart failure. They are particularly helpful in evaluating unexplained dyspnea.
5.2.2 Cardiac biomarkers
Cardiac biomarkers may indicate myocardial injury or strain. They can aid in the assessment of acute presentations.
5.2.3 Renal function and electrolytes
Kidney function and electrolyte measurements are essential because heart failure and its treatment can affect sodium, potassium, and creatinine levels. These tests guide safe medication use.
5.3 Electrocardiography
Electrocardiography can reveal prior infarction, arrhythmia, conduction delay, chamber enlargement, or ischemic changes. Although not diagnostic on its own, it often provides important clues.
5.4 Chest radiography
Chest radiography may show cardiomegaly, pulmonary vascular congestion, pleural effusion, or edema. It is useful for assessing alternative causes of dyspnea as well.
5.5 Echocardiography
Echocardiography is a central imaging test in heart failure. It evaluates structure, function, valves, and filling patterns without invasive procedures.
5.5.1 Ejection fraction assessment
Measurement of ejection fraction helps classify the syndrome and guide treatment. Repeated assessment may be used to monitor response.
5.5.2 Valve and chamber evaluation
The study can identify valvular lesions, chamber enlargement, wall motion abnormalities, and structural defects. These findings often reveal the cause.
5.5.3 Diastolic function assessment
Assessment of diastolic function helps determine whether filling is impaired. This is especially relevant in preserved ejection fraction.
5.6 Additional imaging
Other imaging studies are used when echocardiography is insufficient or when more detail is needed about myocardial tissue or anatomy.
5.6.1 Cardiac MRI
Cardiac MRI provides detailed information about myocardial structure, scar, inflammation, and infiltration. It is particularly valuable in cardiomyopathy evaluation.
5.6.2 CT scanning
CT scanning can assess cardiac anatomy and coronary disease in selected cases. It is also helpful when other imaging modalities are limited.
5.7 Hemodynamic assessment
Invasive measurement is reserved for selected patients, especially those with unclear volume status, severe symptoms, or advanced disease. It provides direct data on pressures and output.
5.7.1 Cardiac catheterization
Cardiac catheterization may be used to assess coronary anatomy and hemodynamics. It is important when ischemia is suspected.
5.7.2 Right heart catheterization
Right heart catheterization measures intracardiac and pulmonary pressures. It is useful in complex cases and advanced therapy evaluation.
5.8 Differential diagnosis
Conditions that can resemble heart failure include lung disease, renal disease, liver disease, anemia, and obesity-related breathlessness. Careful evaluation helps distinguish these disorders from true cardiac failure.
6 Management
Management combines lifestyle measures, medications, device-based therapy, procedures, and treatment of the underlying cause. The approach is individualized according to severity, ejection fraction, and associated conditions.
6.1 General measures
Nonpharmacological measures support symptom control and reduce exacerbations. They also improve adherence and long-term self-management.
6.1.1 Diet and sodium restriction
Limiting sodium intake can reduce fluid retention and ease congestion. Dietary counseling is often part of routine care.
6.1.2 Fluid management
Fluid restriction may be recommended in selected patients with marked congestion or hyponatremia. Daily weight monitoring helps detect fluid shifts early.
6.1.3 Exercise and rehabilitation
Supervised exercise and rehabilitation can improve functional capacity and quality of life. Programs are tailored to tolerance and clinical stability.
6.1.4 Patient education and self-monitoring
Education covers symptom recognition, medication adherence, and warning signs of decompensation. Self-monitoring of weight and swelling can prompt earlier intervention.
6.2 Pharmacological treatment
Drug therapy aims to relieve symptoms, reduce hospitalizations, and improve survival when indicated. The specific regimen depends on the heart failure phenotype and comorbidities.
6.2.1 Diuretics
Diuretics reduce fluid overload and are central for symptomatic relief. They do not correct the underlying cardiac defect but help control congestion.
6.2.2 ACE inhibitors and ARBs
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce neurohormonal activation and lower afterload. They are important in many patients with reduced ejection fraction.
6.2.3 ARNIs
Angiotensin receptor-neprilysin inhibitors combine blockade of the renin-angiotensin system with enhanced natriuretic peptide activity. They are used in selected patients to improve outcomes.
6.2.4 Beta blockers
Beta blockers counter excessive sympathetic activation and can improve survival in chronic heart failure. They are introduced carefully and titrated gradually.
6.2.5 Mineralocorticoid receptor antagonists
These agents reduce aldosterone-mediated sodium retention and fibrosis. They are commonly added in appropriate patients with persistent symptoms or reduced ejection fraction.
6.2.6 SGLT2 inhibitors
Sodium-glucose cotransporter 2 inhibitors have become important in heart failure management. They provide benefits beyond glucose lowering and are used in multiple heart failure populations.
6.2.7 Vasodilators
Vasodilators reduce vascular resistance and may improve forward flow in selected patients. They are also used in some acute settings.
6.2.8 Digoxin
Digoxin can improve symptoms and help control heart rate in some patients, especially those with atrial fibrillation. Its use requires attention to renal function and drug interactions.
6.3 Acute decompensated heart failure treatment
Acute worsening often requires urgent stabilization. Treatment focuses on oxygenation, decongestion, and support of circulation.
6.3.1 Oxygen and ventilatory support
Supplemental oxygen and noninvasive ventilation may relieve respiratory distress. These measures are particularly helpful in pulmonary edema.
6.3.2 Intravenous diuretics
Intravenous diuretics are commonly used to rapidly reduce fluid overload. Response is monitored by urine output, symptoms, and laboratory values.
6.3.3 Inotropes
Inotropes may be used in low-output states with poor perfusion. They are generally reserved for severe or refractory cases because of potential risks.
6.3.4 Vasodilator therapy
Intravenous vasodilators can reduce preload and afterload in selected patients with adequate blood pressure. They may quickly improve dyspnea and congestion.
6.4 Device therapy
Devices are used to reduce sudden death risk, improve synchrony, or support circulation in advanced disease. Their role depends on the underlying cardiac substrate.
6.4.1 Implantable cardioverter-defibrillator
An implantable cardioverter-defibrillator can detect and terminate life-threatening arrhythmias. It is considered in patients at elevated risk of sudden cardiac death.
6.4.2 Cardiac resynchronization therapy
Cardiac resynchronization therapy improves coordinated ventricular contraction in selected patients with conduction delay. It can enhance symptoms and ventricular performance.
6.4.3 Ventricular assist devices
Ventricular assist devices mechanically support circulation in advanced heart failure. They may serve as a bridge to transplantation or as long-term therapy in selected cases.
6.5 Surgical and interventional treatment
Procedures are used when the underlying structural problem is correctable or when disease is advanced enough to require definitive intervention.
6.5.1 Revascularization
Revascularization may improve symptoms and function when ischemia is driving ventricular dysfunction. It is considered in appropriate coronary disease.
6.5.2 Valve repair or replacement
Correcting significant valvular lesions can reduce volume or pressure overload. Timing depends on severity, symptoms, and overall cardiac function.
6.5.3 Heart transplantation
Heart transplantation is reserved for end-stage heart failure that is refractory to other therapies. It offers the possibility of long-term survival in carefully selected patients.
6.6 Palliative and supportive care
Supportive care addresses symptom relief, psychological needs, and decision-making in advanced disease. It can be integrated alongside disease-directed therapy at any stage.
7 Complications
Heart failure can lead to progressive organ dysfunction and life-threatening events. Complications may arise from congestion, low perfusion, arrhythmia, or treatment limitations.
7.1 Acute pulmonary edema
Pulmonary edema is a severe accumulation of fluid in the lungs that causes marked respiratory distress. It is a medical emergency.
7.2 Cardiorenal syndrome
Cardiorenal syndrome refers to the interplay between heart failure and kidney dysfunction. Each condition can worsen the other through hemodynamic and neurohormonal mechanisms.
7.3 Arrhythmias
Atrial and ventricular rhythm disturbances are common in heart failure. They may worsen symptoms, reduce output, and increase risk of sudden events.
7.4 Thromboembolism
Blood stasis within a dilated heart or atrium may promote clot formation. Embolic complications can affect the brain or other organs.
7.5 Hepatic congestion
Chronic venous congestion can impair liver function and cause discomfort or abnormal laboratory results. Advanced cases may lead to fibrosis.
7.6 Cachexia
Cachexia is involuntary weight loss with muscle wasting and weakness. It is associated with advanced disease and poorer outcomes.
7.7 Sudden cardiac death
Sudden cardiac death may result from malignant arrhythmias or profound pump failure. Preventive strategies depend on risk assessment.
8 Prognosis
The outlook in heart failure varies widely according to cause, severity, comorbidity, and response to therapy. Some patients remain stable for years, while others experience recurrent decompensation.
8.1 Predictors of outcome
Important prognostic factors include functional class, ejection fraction, renal function, age, and the presence of ischemic disease or arrhythmia. Biomarkers and exercise tolerance may also help estimate risk.
8.2 Mortality and hospitalization risk
Heart failure is associated with substantial mortality and frequent hospital admissions. Risk increases with advanced symptoms, repeated exacerbations, and coexisting organ dysfunction.
8.3 Quality of life
Symptoms often limit daily activity and independence. Effective therapy can improve physical functioning, sleep, and emotional well-being.
8.4 Recurrence and readmission
Readmission is common after acute decompensation, especially when medication adherence, fluid control, or follow-up is incomplete. Close outpatient monitoring reduces recurrence.
9 Prevention
Prevention focuses on reducing the development of structural heart disease and limiting progression in people already at risk. Many measures overlap with general cardiovascular prevention.
9.1 Primary prevention
Primary prevention aims to stop heart failure before it begins by controlling risk factors and preventing myocardial injury.
9.1.1 Blood pressure control
Adequate blood pressure management reduces the long-term strain on the heart. It is one of the most effective preventive measures.
9.1.2 Lipid management
Control of blood lipids lowers the risk of coronary disease and myocardial infarction. This indirectly reduces later heart failure.
9.1.3 Diabetes management
Good glycemic control helps limit vascular and myocardial damage. It also reduces the burden of related comorbidities.
9.1.4 Smoking cessation
Stopping tobacco use lowers cardiovascular risk and improves overall vascular health. It is a key preventive intervention.
9.2 Secondary prevention
Secondary prevention applies after myocardial injury or when structural heart disease is already present. The goal is to slow progression and avoid decompensation.
9.2.1 Post-myocardial infarction care
After infarction, appropriate follow-up and medication can reduce remodeling and later failure. Early treatment of ischemia is especially important.
9.2.2 Risk factor modification
Lifestyle changes and medical treatment of comorbidities help reduce worsening of established disease. This includes attention to diet, activity, and adherence.
9.2.3 Long-term follow-up
Regular follow-up supports dose adjustment, symptom assessment, and early detection of deterioration. It also reinforces patient education.
10 Epidemiology
Heart failure is a common chronic cardiovascular disorder worldwide. Its frequency rises with age and with the prevalence of ischemic heart disease, hypertension, and diabetes.
10.1 Global prevalence
The condition affects millions of people globally and represents a major public health burden. Prevalence varies by region, age structure, and access to care.
10.2 Age and sex distribution
Heart failure becomes more common with advancing age. Men and women may differ in underlying causes and in the frequency of preserved versus reduced ejection fraction.
10.3 Hospitalization burden
Heart failure is a leading reason for cardiovascular hospitalization, particularly among older adults. Recurrent admissions contribute substantially to healthcare use.
10.4 Mortality trends
Outcomes have improved in many settings because of better medical and device therapy, but mortality remains significant. Chronic comorbidity and advanced age continue to affect survival.
11 History
Understanding of heart failure has evolved from descriptive observations to a syndrome defined by imaging, biomarkers, and targeted therapy. Progress in cardiology has greatly refined diagnosis and treatment.
11.1 Early descriptions
Early medical accounts described swelling, breathlessness, and fluid accumulation as signs of cardiac weakness. These observations laid the foundation for later clinical classification.
11.2 Development of diagnostic methods
The introduction of auscultation, electrocardiography, radiography, and echocardiography transformed assessment of cardiac function. Later biochemical testing added further precision.
11.3 Evolution of medical therapy
Treatment advanced from rest and symptom relief to diuretics, vasodilators, neurohormonal blockade, and device therapy. Each stage improved the ability to control symptoms and prolong life.
11.4 Modern guideline-based care
Contemporary management is guided by evidence-based recommendations that integrate medications, procedural options, and follow-up. Care is tailored to phenotype, risk, and response.
12 Research directions
Research continues to refine heart failure classification, improve outcomes, and identify treatments that target disease mechanisms more precisely. Current work spans drugs, biomarkers, regenerative medicine, and individualized care.
12.1 Novel drug therapies
New medications aim to affect inflammation, metabolism, fibrosis, and myocardial energetics. Many are being tested for specific subgroups of patients.
12.2 Biomarkers
Biomarkers are being studied to improve early diagnosis, risk stratification, and treatment monitoring. The goal is to identify worsening disease before major decompensation occurs.
12.3 Gene and cell-based approaches
Gene and cell-based strategies seek to restore damaged myocardium or improve contractile function. These remain experimental but represent an active area of investigation.
12.4 Precision medicine
Precision medicine attempts to match therapy to the patient’s underlying biology, comorbidities, and disease pattern. It may eventually improve selection of treatments and predict response more accurately.